CHEOF (Cochlear) Other Financing: $-41 Mil (TTM As of Dec. 2025)


CHEOF Cochlear Ltd CHEOF
62 GF Score
Price $81.42
GF Value $210.35
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Cochlear Other Financing?

Cochlear CHEOF 62 Other Financing is $-41 Mil as of Dec. 2025. GuruFocus rates CHEOF with a GF Score™ of 62/100 and a GF Value™ of $210.35 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Cochlear's Other Financing for the six months ended in Dec. 2025 was $-28 Mil.

Cochlear's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was $-41 Mil.

Cochlear Other Financing Historical Data

* Premium members only.

The historical data trend for Cochlear's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cochlear Other Financing Chart

Cochlear Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.67 -17.99 -28.26 -23.37 -39.39

Cochlear Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.25 -10.23 -25.84 -12.83 -28.17
CHEOF
62GF Score
Cochlear Ltd CHEOF
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cochlear Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-41 Mil mean?
Cochlear (CHEOF) has a Other Financing of $-41 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Cochlear and its competitors.
Is Cochlear's Other Financing too high?
Cochlear's current Other Financing is $-41 Mil. Overall, Cochlear has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cochlear's Other Financing compare to ABT and SYK?
Cochlear's Other Financing of $-41 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Devices & Instruments company?
A good Other Financing depends on the Medical Devices & Instruments industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Cochlear and its competitors. Cochlear's current Other Financing is $-41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cochlear stock overvalued right now?
Based on GuruFocus' analysis, Cochlear (CHEOF) is currently considered Significantly Undervalued. The stock's GF Value™ is $210.35, compared to a current price of $81.42 — trading 61.3% below its estimated fair value. The current Other Financing is $-41 Mil. Cochlear's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Cochlear (CHEOF), the current Other Financing is $-41 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cochlear (CHEOF) Overvalued in 2026?

Based on GuruFocus' analysis, Cochlear stock appears to be undervalued. The current stock price of $81.42 is trading 61.3% below its estimated GF Value™ of $210.35. GuruFocus considers Cochlear to be Significantly Undervalued.

Key valuation signals for CHEOF:

  • Other Financing: $-41 Mil
  • GF Value™: $210.35 vs. price of $81.42 (61.3% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the CHEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cochlear Business Description

Address 1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
62GF Score

Get the complete analysis for CHEOF

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$81.42
Price
$210.35
GF Value